Tatva Chintan Pharma Chem growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+32.2%−2.7%−7.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+172.3%−49.8%+12.6%
+759.2%−84.6%−16.5%
+636.1%−81.2%−33.3%
+636.9%−81.6%−35.4%
+20.0%+2.1%+8.3%
+5.8%+0.2%+43.2%
+27.6%−74.8%+252.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals
₹ CrorePeersVISHNUJUBLCPLKIRIINDUSFOSECOINDCHEMPLASTSDDEVPLSTIKGUJALKALIYASHOMcap ₹3,777 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-7.1-2.7+32.2—
EBITDA Growth—+12.6-49.8+172.3—
EBIT Growth—-16.5-84.6+759.2—
Net Income Growth—-33.3-81.2+636.1—
EPS Growth—-35.4-81.6+636.9—
Total Assets Growth—+8.3+2.1+20.0—
Total Equity Growth—+43.2+0.2+5.8—
Cash from Operations Growth—+252.9-74.8+27.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.